Show simple item record

dc.contributor.authorStordal, Britta
dc.contributor.authorPavlakis, Nick
dc.contributor.authorDavey, Ross
dc.date.accessioned2009-11-11T04:13:30Z
dc.date.available2009-11-11T04:13:30Z
dc.date.issued2009
dc.identifier.citationStordal B, Pavlakis N, Davey R. Treating Cisplatin-Resistant Cancer: A Systematic Analysis of Oxaliplatin or Paclitaxel Salvage Chemotherapy. Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. 2009. Humana Press. p.225-30.en
dc.identifier.urihttp://hdl.handle.net/2123/5686
dc.description.abstractObjective: To examine the pre-clinical and clinical evidence for the use of oxaliplatin or paclitaxel salvage chemotherapy in patients with cisplatin-resistant cancer. Methods: Medline was searched for 1) Cell models of acquired resistance reporting cisplatin, oxaliplatin and paclitaxel sensitivities and 2) Clinical trials of single agent oxaliplatin or paclitaxel salvage therapy for cisplatin/carboplatin-resistant ovarian cancer. Results: Oxaliplatin - Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. In contrast, data in cell models suggests that there is crossresistance between cisplatin and oxaliplatin in cellular models with resistance levels which reflect clinical resistance (<10 fold). Oxaliplatin as a single agent had a poor response rate in patients with cisplatin-resistant ovarian cancer (8%, n=91). Oxaliplatin performed better in combination with other agents for the treatment of platinum-resistant cancer suggesting that the benefit of oxaliplatin may lie in its more favourable toxicity and ability to be combined with other drugs rather than an underlying activity in cisplatin resistance. Oxaliplatin therefore should not be considered broadly active in cisplatin-resistant cancer. Paclitaxel – Cellular data 2 suggests that paclitaxel is active in cisplatin-resistant cancer. 68.1% of cisplatinresistant cells were sensitive to paclitaxel. Paclitaxel as a single agent had a response rate of 22% in patients with platinum-resistant ovarian cancer (n = 1918), a significant increase from the response of oxaliplatin (p<0.01). Paclitaxel-resistant cells were also sensitive to cisplatin, suggesting that alternating between agents may be beneficial. Studies of single agent paclitaxel in platinum-resistant ovarian cancer where patients had previously received paclitaxel had an improved response rate of 35.3% n=232 (p<0.01), suggesting that pre-treatment with paclitaxel improves the response of salvage paclitaxel therapy. Conclusions: Cellular models reflect the resistance observed in the clinic as the cross resistant agent oxaliplatin has a lower response rate compared to the non-cross resistant agent paclitaxel in cisplatin-resistant ovarian cancer. Alternating therapy with cisplatin and paclitaxel may therefore lead to an improved response rate in ovarian cancer.en
dc.language.isoenen
dc.publisherHumana Pressen
dc.rightsThe University of Sydney claims copyright ownership of all information stored on this site, unless expressly stated otherwise.en
dc.subjectCisplatinen
dc.subjectOxaliplatinen
dc.subjectPaclitaxelen
dc.subjectResistanceen
dc.subjectOvarian canceren
dc.subjectSalvage chemotherapyen
dc.titleTreating cisplatin-resistant cancer: a systematic analysis of oxaliplatin or paclitaxel salvage chemotherapy.en
dc.typeBook chapteren
dc.contributor.departmentBill Walsh Cancer Research Laboratoriesen
dc.identifier.doihttp://dx.doi.org/10.1007/978-1-60327-459-3_27


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record